Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine
Agency IQ
SEPTEMBER 15, 2023
Of the other three comments on the Citizen Petition docket, one supportive comment came from researchers who conducted studies supportive of the petitioner’s assertion of lack of symptomatic efficacy for phenylephrine. Their research showed that consumers prefer oral formulations over intranasal at a rate of 3 to 1.
Let's personalize your content